{"groups":[{"description":"Oral pomalidomide 4 mg on Days 1-21 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity","id":"FG000","title":"Pomalidomide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"50"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"1 discontinued before starting drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"74"}],"type":"STARTED"},{"achievements":[{"comment":"Safety Population includes those who were enrolled and received at least one dose of study drug","groupId":"FG000","numSubjects":"73"}],"type":"Safety Population"},{"achievements":[{"comment":"Participants who received ≥ 1 dose of study drug and had at least 1 postbaseline efficacy assessment","groupId":"FG000","numSubjects":"64"}],"type":"Efficacy Evaluable Population (EEP)"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"74"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"CC-4047-MM003C is a companion study for the trial CC-4047-MM-003 (NCT01311687). CC-4047-MM-003C enrolled those who discontinued treatment with dexamethasone alone (Treatment Arm B) in the CC-4047-MM-003 trial due to disease progression; those who had discontinued treatment with pomalidomide plus dexamethasone (Arm A) were not eligible to enroll"}